Clinical Trials Directory

Trials / Completed

CompletedNCT03734783

IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB

Regulate Effect of Il-35 Secreting Breg Cells on Tcells and on Diseases Progression in Patients With CHB

Status
Completed
Phase
Study type
Observational
Enrollment
55 (actual)
Sponsor
Changhai Hospital · Academic / Other
Sex
All
Age
17 Years – 70 Years
Healthy volunteers
Accepted

Summary

The investigators observed the level of IL-35 secreting B regulatory (IL-35+Bregs) cells in peripheral blood cells in patients with chronic hepatitis B, and analysed the relationship between the IL-35+Bregs level and disease stage, and Th1 and Th2 cells level.

Detailed description

Regulatory B cells (Bregs) are involved in the immune tolerance process through multiple pathways and Bregs are involved in the process of chronic HBV infection. Here the investigators intended to investigate the regulating role and the mechanism of CD19+ IL-35+ cells on host T cell immune during chronic HBV infection by using in vitro cell sorting, B cell differentiation induction, Transwell cell co-culture system and other methods.

Conditions

Timeline

Start date
2017-07-01
Primary completion
2019-11-15
Completion
2019-11-15
First posted
2018-11-08
Last updated
2019-11-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03734783. Inclusion in this directory is not an endorsement.

IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB (NCT03734783) · Clinical Trials Directory